Search in:

Advanced search

Expert Opinion on Emerging Drugs Volume 13, 2008 - Issue 3

Submit an article Journal homepage

511

Views

CrossRef citations to date

Altmetric

Reviews

Emerging antiviral drugs

Erik De Clercq Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium +32 16 337367; +32 16 337340; [email protected]

Pages 393-416 | Published online: 02 Sep 2008

Cite this article
https://doi.org/10.1517/14728214.13.3.393

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

De Clercq E. Three decades of antiviral drugs (Editorial). Nat Rev Drug Discov 2007;6:941
Web of Science ®Google Scholar
Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74:5716-20
PubMed Web of Science ®Google Scholar
Schaeffer HJ, Beauchamp L, de Miranda P, et al. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978;272:583-5
PubMed Web of Science ®Google Scholar
De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007;6:1001-18
PubMed Web of Science ®Google Scholar
Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Discov 2007;6:959-66
PubMed Web of Science ®Google Scholar
Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90
PubMed Web of Science ®Google Scholar
Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment: finding the right path. Nat Rev Drug Discov 2007;6:991-1000
PubMed Web of Science ®Google Scholar
Férir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 2008;18:19-34
PubMed Web of Science ®Google Scholar
De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006;5:1015-25
PubMed Web of Science ®Google Scholar
Von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007;6:967-74
PubMed Web of Science ®Google Scholar
De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004;2:704-20
PubMed Web of Science ®Google Scholar
De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-96
PubMed Web of Science ®Google Scholar
Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005;5:1997-2004
PubMed Web of Science ®Google Scholar
Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2004;17:658-65
PubMed Web of Science ®Google Scholar
Viallard JF, Lazaro E, Lafon ME, Pellegrin JL. Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2005;46:1659-62
PubMed Web of Science ®Google Scholar
Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006;8:95-101
PubMed Web of Science ®Google Scholar
Lebeau I, Andrei G, Krečmerová M, et al. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob Agents Chemother 2007;51:2268-73
PubMed Web of Science ®Google Scholar
Bonatti H, Aigner F, De Clercq E, et al. Local administration of cidofovir for human papilloma virus-associated skin lesions in transplant recipients. Transpl Int 2007;20:238-46
PubMedGoogle Scholar
Schinkmanová M, Votruba I, Holý A. N6-methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates. Biochem Pharmacol 2006;71:1370-6
PubMed Web of Science ®Google Scholar
Plumpton M, Sharp NA, Liddicoat LH, et al. A high capacity assay for inhibitors of human papillomavirus DNA replication. Biotechnology 1995;13:1210-4
PubMedGoogle Scholar
White PW, Faucher A-M, Massariol M-J, et al. Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother 2005;49:4834-42
PubMed Web of Science ®Google Scholar
Crute JJ, Grygon CA, Hargrave KD, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002;8:386-91
PubMed Web of Science ®Google Scholar
Kleymann G, Fischer R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002;8:392-8
PubMed Web of Science ®Google Scholar
Spector FC, Liang L, Giordano H, et al. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J Virol 1998;72:6979-87
PubMed Web of Science ®Google Scholar
Betz UAK, Fischer R, Kleymann G, et al. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother 2002;46:1766-72
PubMed Web of Science ®Google Scholar
Baumeister J, Fischer R, Eckenberg P, et al. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antiviral Chem Chemother 2007;18:35-48
PubMedGoogle Scholar
Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res 2007;75:30-5
PubMed Web of Science ®Google Scholar
Liuzzi M, Kibler P, Bousquet C, et al. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res 2004;64:161-70
PubMed Web of Science ®Google Scholar
Biswas S, Swift M, Field HJ. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antiviral Chem Chemother 2007;18:13-23
PubMedGoogle Scholar
Biswas S, Smith C, Field HJ. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1. J Antimicrob Chemother 2007;60:274-9
PubMed Web of Science ®Google Scholar
Biswas S, Jennens L, Field HJ. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch Virol 2007;152:1489-500
PubMed Web of Science ®Google Scholar
McGuigan C, Yarnold CJ, Jones G, et al. Potent and selective inhibition of varicella–zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 1999;42:4479-84
PubMed Web of Science ®Google Scholar
McGuigan C, Barucki H, Blewett S, et al. Highly potent and selective inhibition of varicella–zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000;43:4993-7
PubMed Web of Science ®Google Scholar
De Clercq E. Highly potent and selective inhibition of varicella–zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Med Res Rev 2003;23:253-74
PubMed Web of Science ®Google Scholar
Andrei G, Sienaert R, McGuigan C, et al. Susceptibilities of several clinical varicella–zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob Agents Chemother 2005;49:1081-6
PubMed Web of Science ®Google Scholar
Sienaert R, Naesens L, Brancale A, et al. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella–zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol 2002;61:249-54
PubMed Web of Science ®Google Scholar
McGuigan C, Pathirana RN, Migliore M, et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother 2007;60:1316-30
PubMed Web of Science ®Google Scholar
Canas SM, Wargin B, Boehlecke B, et al. A single accelerating dose study to evaluate safety and pharmacokinetics (PK) of FV-100 in healthy subjects. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec. Antiviral Res 2008;A32:40
Google Scholar
Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71:154-63
PubMed Web of Science ®Google Scholar
Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002;46:2365-72
PubMed Web of Science ®Google Scholar
Chou S, Van Wechel LC, Marousek GI. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007;196:91-4
PubMed Web of Science ®Google Scholar
Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 2008;82:246-53
PubMed Web of Science ®Google Scholar
De Clercq E, Naesens L. In search of effective anti-HHV-6 agents. J Clin Virol 2006; 37(Suppl 1):S82-6
PubMed Web of Science ®Google Scholar
Naesens L, Bonnafous P, Agut H, De Clercq E. Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J Clin Virol 2006;37(Suppl 1):S69-75
PubMed Web of Science ®Google Scholar
Prichard M, Daily S, Perry A, Kern E. Maribavir inhibits the replication of human herpesvirus 6 and the activity of the U69 protein kinase. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec. Antiviral Res 2008;A29:34
Google Scholar
Chapenko S, Krumina A, Kozireva S, et al. Activation of human herpesviruses 6 and 7 in patients with chronic fatigue syndrome. J Clin Virol 2006;37(Suppl 1):S47-51
PubMed Web of Science ®Google Scholar
Kogelnik AM, Loomis K, Hoegh-Petersen M, et al. Use of valganciclovir in patients with elevated antibody titers against human herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006;37(Suppl 1):S33-8
PubMed Web of Science ®Google Scholar
Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007;21:707-14
PubMed Web of Science ®Google Scholar
De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 2007;75:1-13
PubMed Web of Science ®Google Scholar
Neyts J, Leyssen P, Verbeken E, De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother 2004;48:2267-73
PubMed Web of Science ®Google Scholar
Geerinck K, Lukoto G, Snoeck R, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol 2001;64:543-9
PubMed Web of Science ®Google Scholar
Fery-Blanco C, Pelletier F, Humbert P, Aubin F. Disseminated molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus: efficacy of cidofovir. Ann Dermatol Venereol 2007;134:457-9
PubMed Web of Science ®Google Scholar
Jones S, Kress D. Treatment of molluscum contagiosum and herpes simplex virus cutaneous infections. Cutis 2007;79(Suppl 4):11-17
PubMed Web of Science ®Google Scholar
Magee WC, Aldern KA, Hostetler KY, Evans DH. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob Agents Chemother 2008;52:586-97
PubMed Web of Science ®Google Scholar
Duraffour S, Snoeck R, de Vos R, et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antiviral Ther 2007;12:1205-16
PubMed Web of Science ®Google Scholar
Dal Pozzo F, Andrei G, Lebeau I, et al. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res 2007;75:52-7
PubMed Web of Science ®Google Scholar
Quenelle DC, Collins DJ, Herror BP, et al. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother 2007;51:3940-7
PubMed Web of Science ®Google Scholar
Beadle JR, Wan WB, Ciesla SL, et al. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J Med Chem 2006;49:2010-5
PubMed Web of Science ®Google Scholar
Hostetler KY, Beadle JR, Trahan J, et al. Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Res 2007;73:212-8
PubMed Web of Science ®Google Scholar
Ruiz JC, Beadle JR, Aldern KA, et al. Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Res 2007;75:87-90
PubMed Web of Science ®Google Scholar
Bailey TR, Rippin SR, Opsitnick E, et al. N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: identification of novel orthopoxvirus egress inhibitors. J Med Chem 2007;50:1442-4
PubMed Web of Science ®Google Scholar
Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005;79:13139-49
PubMed Web of Science ®Google Scholar
Sbrana E, Jordan R, Hruby D, et al. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 2007;76:768-73
PubMed Web of Science ®Google Scholar
Quenelle DC, Buller RML, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 2007;51:689-95
PubMed Web of Science ®Google Scholar
Kaiser J. A tame virus runs amok. Science 2007;316:1418-9
PubMed Web of Science ®Google Scholar
Grosenbach DW, Jordan R, King DS, et al. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 2008;26:933-46
PubMed Web of Science ®Google Scholar
Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007;51:4118-24
PubMed Web of Science ®Google Scholar
Jordan R, Jones K, Bolken T, et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Quebec, Canada. Antiviral Res 2008;A32:41
Google Scholar
Smee DF, Hurst BL, Wong MH, et al. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Antiviral Res 2007;76:124-9
PubMed Web of Science ®Google Scholar
Marquez VE, Hughes SH, Sei S, Agbaria R. The history of N-methanocarbathymidine: the investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent. Antiviral Res 2006;71:268-75
PubMed Web of Science ®Google Scholar
Deng L, Dai P, Ciro A, et al. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol 2007;81:13392-402
PubMed Web of Science ®Google Scholar
Osborn MK, Lok ASF. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006;57:1030-4
PubMed Web of Science ®Google Scholar
Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 2006;71:206-15
PubMed Web of Science ®Google Scholar
Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. J Med Virol 2006;78:1025-34
PubMed Web of Science ®Google Scholar
Van der Molen RG, Sprengers D, Biesta PJ, et al. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006;44:907-14
PubMed Web of Science ®Google Scholar
Delaney WE IV. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 2007;59:827-32
PubMed Web of Science ®Google Scholar
Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antiviral Ther 2007;12:355-62
PubMed Web of Science ®Google Scholar
Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther 2006;6:913-21
PubMed Web of Science ®Google Scholar
Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol 2006;36:8-12
PubMed Web of Science ®Google Scholar
Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11
PubMed Web of Science ®Google Scholar
Dimou E, Papadimitropoulos V, Hadziyannis S. The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag 2007;3:1077-86
PubMedGoogle Scholar
O'Brien WA. Entecavir has low resistance rates after 5-year treatment of chronic hepatitis B [cited 2008 May 30]. Available from: http://www.docguide.com/news/content.nsf/news/
Google Scholar
Hirsch MS. Entecavir surprise. N Engl J Med 2007;356:2641-3
PubMed Web of Science ®Google Scholar
McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir – effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21
PubMed Web of Science ®Google Scholar
Ruiz-Sancho A, Sheldon J, Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 2007;7:751-61
PubMed Web of Science ®Google Scholar
Buster EHCJ, Hansen BE, Butti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007;46:388-94
PubMed Web of Science ®Google Scholar
Johnson RM, Ristig MB, Overton ET, et al. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007;8:173-81
PubMed Web of Science ®Google Scholar
Sasadeusz JJ, Locarnini SL, Macdonald G. Why do we not yet have combination chemotherapy for chronic hepatitis B? Med J Aust 2007;186:204-6
PubMed Web of Science ®Google Scholar
Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84
PubMed Web of Science ®Google Scholar
Menne S, Asif G, Narayanasamy J, et al. Antiviral effect of orally administered (-)-beta-d-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 2007;51:3177-84
PubMed Web of Science ®Google Scholar
Choo H, Beadle JR, Kern ER, et al. Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters. Antimicrob Agents Chemother 2007;51:611-5
PubMed Web of Science ®Google Scholar
Brunelle MN, Lucifora J, Neyts J, et al. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007;51:2240-3
PubMed Web of Science ®Google Scholar
Reddy KR, Matelich MC, Ugarkar BG, et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem 2008;51:666-76
PubMed Web of Science ®Google Scholar
Wright MF, Modlin JF. The demise and rebirth of polio – a modern Phoenix? J Infect Dis 2008;197:335-6
PubMed Web of Science ®Google Scholar
Estívariz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island – Indonesia, 2005. J Infect Dis 2008;197:347-54
PubMed Web of Science ®Google Scholar
De Palma AM, Pürstinger G, Wimmer E, et al. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 2008;14:545-51
PubMed Web of Science ®Google Scholar
Ledford RM, Patel NR, Demenczuk TM, et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 2004;78:3663-74
PubMed Web of Science ®Google Scholar
Patick AK Rhinovirus chemotherapy. Antiviral Res 2006;71:391-6
PubMed Web of Science ®Google Scholar
Binford SL, Weady PT, Maldonado WF, et al. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2007;51:4366-73
PubMed Web of Science ®Google Scholar
Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003;47:3907-16
PubMed Web of Science ®Google Scholar
De Palma AM, Heggermont W, Leyssen P, et al. Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo [3,4-a]benzimidazoles. Biochem Biophys Res Commun 2007;353:628-32
PubMed Web of Science ®Google Scholar
De Palma AM, Heggermont W, Lanke K, et al. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol 2008;82:4720-30
PubMed Web of Science ®Google Scholar
Padalko E, Verbeken E, Matthys P, et al. Mycophenolate mofetil inhibits the development of Coxsackie B3-induced myocarditis in mice. BMC Microbiol 2003;3:25
PubMedGoogle Scholar
Padalko E, Nuyens D, De Palma A, et al. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 2004;48:267-74
PubMed Web of Science ®Google Scholar
Lagoja IM, De Clercq E. Anti-influenza virus agents: synthesis and mode of action. Med Res Rev 2008;28:1-38
PubMed Web of Science ®Google Scholar
Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78:91-102
PubMed Web of Science ®Google Scholar
Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008;374:198-209
PubMed Web of Science ®Google Scholar
Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006;69:39-45
PubMed Web of Science ®Google Scholar
Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007;51:845-51
PubMed Web of Science ®Google Scholar
Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005;49:981-6
PubMed Web of Science ®Google Scholar
Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007;51:3168-76
PubMed Web of Science ®Google Scholar
Gowen B, Wong M-H, Jung K-H, et al. Therapy of advanced arenaviral infection in hamsters with T-705. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 Apr 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A57:105
Google Scholar
Sidwell RW, Barnard DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res 2006;7:379-90
Google Scholar
Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 2007;51:3346-53
PubMed Web of Science ®Google Scholar
Leyssen P, Charlier N, Paeshuyse J, et al. Prospects for antiviral therapy. Adv Virus Res 2003;61:511-53
PubMedGoogle Scholar
Leyssen P, Croes R, Rau P, et al. Acute encephalitis, a poliomyelitis-like syndrome and neurological sequelae in a hamster model for flavivirus infections. Brain Pathol 2003;13:279-90
PubMed Web of Science ®Google Scholar
Leyssen P, Drosten C, Paning M, et al. Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother 2003;47:777-82
PubMed Web of Science ®Google Scholar
Julander JG, Furuta Y, Shafer K, Sidwell RW. Activity of T-1106 in a hamster model of Yellow fever virus infection. Antimicrob Agents Chemother 2007;51:1962-6
PubMed Web of Science ®Google Scholar
Julander J, Shafer K, Smee D, et al. Efficacy of T-1106 or T-705, alone or in combination with ribavirin, in the treatment of hamsters infected with Yellow fever virus. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A34:46
Google Scholar
Sun Y, Chung D-H, Chu Y-K, Jonsson CB, Parker WB. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob Agents Chemother 2007;51:84-8
PubMed Web of Science ®Google Scholar
Kaptein S, Jacobs M, Gamarnik A, et al. A derivative of the antibiotic doxorubicin inhibits Dengue and Yellow fever virus replication in vitro Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A33:44
Google Scholar
Schul W, Liu W, Xu H-Y, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007;195:665-74
PubMed Web of Science ®Google Scholar
Njoroge FG, Chen KX, Shih NY, Piwinski JJ. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008;41:50-9
PubMed Web of Science ®Google Scholar
Slater MJ, Amphlett EM, Andrews DM, et al. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J Med Chem 2007;50:897-900
PubMed Web of Science ®Google Scholar
Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-8
PubMed Web of Science ®Google Scholar
Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9
PubMed Web of Science ®Google Scholar
Ludmerer S, Graham D, Handt L, et al. Evaluation of MK-7009, a novel macrocyclic inhibitor of NS3/4A protease, in the chimpanzee model of chronic hepatitis C virus infection. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Quebec, Canada. Antiviral Res 2008;A23:20
Google Scholar
He Y, King MS, Kempf DJ, et al. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother 2008;52:1101-10
PubMed Web of Science ®Google Scholar
McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non-nucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-12
PubMed Web of Science ®Google Scholar
Le Pogam S, Seshaadri A, Kosaka A, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008;61:1205-16
PubMed Web of Science ®Google Scholar
Murakami E, Niu C, Bao H, et al. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008;52:458-64
PubMed Web of Science ®Google Scholar
Ma H, Jiang WR, Robledo N, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor β-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007;282:29812-20
PubMed Web of Science ®Google Scholar
Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007;51:503-9
PubMed Web of Science ®Google Scholar
Wyles DL, Schooley RT, Kaihara KA, et al. Anti-hepatitis C virus replicon activity of alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonates. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A21:15
Google Scholar
Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008;82:764-74
PubMed Web of Science ®Google Scholar
Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-6
PubMed Web of Science ®Google Scholar
Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005;79:12773-82
PubMed Web of Science ®Google Scholar
Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38
PubMed Web of Science ®Google Scholar
Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48
PubMed Web of Science ®Google Scholar
Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007;21:1449-55
PubMed Web of Science ®Google Scholar
Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antiviral Ther 2007;12:789-96
PubMed Web of Science ®Google Scholar
van't Klooster G, Verloes R, Baert L, et al. Long-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings [abstract 134]. 15th Conference on Retroviruses and Opportunistic Infections; 2008
Google Scholar
Zhang Z, Xu W, Koh Y-H, et al. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2007;51:429-37
PubMed Web of Science ®Google Scholar
Elinder M, Danielson H, Unge T, et al. MIV-170, a novel NNRTI exhibiting tight binding to HIV-1 reverse transcriptase (RT). Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A37:55
Google Scholar
Öberg B, Sahlberg BL, Sahlberg C, et al. MIV-170, a novel NNRTI with potent activity against HIV and HIV mutants. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A51:92
Google Scholar
Watson KM, Yang L, Buckheit CE, Buckheit RW Jr. Development of the dual-acting pyrimidinedione IQP0528 as a vaginal topical anti-HIV microbicide. Abstracts of the 21st International Conference on Antiviral Research; 13 – 17 April 2008; Montreal, Quebec, Canada. Antiviral Res 2008;A26:26
Google Scholar
Tucker TJ, Saggar S, Sisko JT, et al. Discovery of MK-4965: a potent, orally bioavailable HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI) with improved potency against key mutant viruses I. Abstracts of the 235th ACS National Meeting; 6 – 10 April 2008; New Orleans, LA. MEDI 174
Google Scholar
Tucker TJ, Saggar S, Sisko JT, et al. Discovery of MK-4965: a potent, orally bioavailable HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI) with improved potency against key mutant viruses II. Abstracts of the 235th ACS National Meeting; 6 – 10 April 2008; New Orleans, LA. MEDI 175
Google Scholar
Nakata H, Amano M, Koh Y, et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother 2007;51:2701-8
PubMed Web of Science ®Google Scholar
Paintsil E, Dutschman GE, Hu R, et al. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother 2007;51:3870-9
PubMed Web of Science ®Google Scholar
Chu CK, Yadav V, Chong YH, Schinazi RF. Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. J Med Chem 2005;48:3949-52
PubMed Web of Science ®Google Scholar
Lennerstrand J, Chu CK, Schinazi RF. Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate. Antimicrob Agents Chemother 2007;51:2078-84
PubMed Web of Science ®Google Scholar
De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007;73:911-22
PubMed Web of Science ®Google Scholar
Balzarini J, Schols D, Van Laethem K, et al. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. J Antimicrob Chemother 2007;59:80-6
PubMed Web of Science ®Google Scholar
Hostetler KY, Aldern KA, Wan WB, et al. Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro Antimicrob Agents Chemother 2006;50:2857-9
PubMed Web of Science ®Google Scholar
Painter GR, Almond MR, Trost LC, et al. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother 2007;51:3505-9
PubMed Web of Science ®Google Scholar
Cihlar T, Ray AS, Boojamra CG, et al. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 2008;52:655-65
PubMed Web of Science ®Google Scholar
Ray AS, Vela JE, Boojamra CG, et al. Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob Agents Chemother 2008;52:648-54
PubMed Web of Science ®Google Scholar
Heredia A, Gilliam B, Latinovic O, et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2007;51:2489-96
PubMed Web of Science ®Google Scholar
Kazmierski WM, Gudmundsson KS, Piscitelli SC. Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-HIV therapy currently in development. Ann Reports Med Chem 2007;42:301-20
Web of Science ®Google Scholar
Baba M, Miyake H, Wang X, et al. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother 2007;51:707-15
PubMed Web of Science ®Google Scholar
Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007;51:2351-8
PubMed Web of Science ®Google Scholar
Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005;49:4911-9
PubMed Web of Science ®Google Scholar
Schürmann D, Fätkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007;21:1293-9
PubMed Web of Science ®Google Scholar
Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
PubMed Web of Science ®Google Scholar
Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003;100:13555-60
PubMed Web of Science ®Google Scholar
Adamson CS, Ablan SD, Boeras I, et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006;80:10957-71
PubMed Web of Science ®Google Scholar
Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007;51:3063-6
PubMed Web of Science ®Google Scholar
Bevirimat (PA-457). Available from: http://www.panacos.com/product_2.htm
Google Scholar
Lai W, Huang L, Ho P, et al. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2008;52:128-36
PubMed Web of Science ®Google Scholar
Rosenwirth B, Billich A, Datema R, et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob Agents Chemother 1994;38:1763-72
PubMed Web of Science ®Google Scholar
Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-22
PubMed Web of Science ®Google Scholar
Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43:761-70
PubMed Web of Science ®Google Scholar
Ptak RG, Gallay PA, Jochmans D, et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother 2008;52:1302-17
PubMed Web of Science ®Google Scholar
Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-26
PubMed Web of Science ®Google Scholar
Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs 2007;8:125-9
PubMed Web of Science ®Google Scholar
De Clercq E. From adefovir to AtriplaTM via tenofovir, VireadTM and TruvadaTM. Future Virol 2006;1:709-15
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Emerging antiviral drugs

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Emerging antiviral drugs

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date